66 38

Cited 6 times in

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study

 JianZhong Zhang  ;  Tsen-Fang Tsai  ;  Min-Geol Lee  ;  Min Zheng  ;  Gang Wang  ;  HongZhong Jin  ;  Jun Gu  ;  RuoYu Li  ;  QuanZhong Liu  ;  Jin Chen  ;  CaiXia Tu  ;  ChunMei Qi  ;  Hua Zhu  ;  William C. Ports  ;  Tim Crook 
 Journal of Dermatological Science, Vol.88(1) : 36-45, 2017 
Journal Title
 Journal of Dermatological Science 
Issue Date
Administration, Oral ; Adult ; Asian Continental Ancestry Group ; China ; Double-Blind Method ; Female ; Humans ; Janus Kinases/antagonists & inhibitors ; Male ; Middle Aged ; Piperidines/therapeutic use* ; Protein Kinase Inhibitors/therapeutic use* ; Psoriasis/drug therapy* ; Pyrimidines/therapeutic use* ; Pyrroles/therapeutic use* ; Republic of Korea ; Severity of Illness Index ; Taiwan ; Treatment Outcome
Asia ; Efficacy ; Janus kinase inhibitor ; Plaque psoriasis ; Safety ; Tofacitinib
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. OBJECTIVE: This study assessed tofacitinib efficacy and safety vs placebo in Asian patients with moderate to severe chronic plaque psoriasis. METHODS: Patients from China mainland, Taiwan, and Korea were randomized 2:2:1:1 to tofacitinib 5mg (N=88), tofacitinib 10mg (N=90), placebo→5mg (N=44), or placebo→10mg (N=44), twice daily (BID) for 52 weeks. Placebo-treated patients advanced to tofacitinib at Week 16. Co-primary efficacy endpoints: proportions of patients achieving Physician's Global Assessment (PGA) response ('clear' or 'almost clear') and proportion achieving ≥75% reduction from baseline Psoriasis Area and Severity Index (PASI75) at Week 16. RESULTS: At Week 16, more patients achieved PGA and PASI75 responses with tofacitinib 5mg (52.3%; 54.6%) and 10mg (75.6%; 81.1%) BID vs placebo (19.3%; 12.5%; all p<0.0001). Of patients with a Week 16 response, 73.6% and 75.0% maintained PGA response, and 76.8% and 84.9% maintained PASI75 to Week 52 with tofacitinib 5mg and 10mg BID, respectively. Over 52 weeks, 2.2-4.5% of patients across treatment groups experienced serious adverse events, and 1.1-6.8% discontinued due to adverse events. CONCLUSION: Tofacitinib demonstrated efficacy vs placebo at Week 16 in Asian patients with moderate to severe plaque psoriasis; efficacy was maintained through Week 52. No unexpected safety findings were observed. [NCT01815424].
Files in This Item:
T201703728.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Min Geol(이민걸) ORCID logo https://orcid.org/0000-0001-7040-5335
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.